Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.12 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.12 per share when it actually produced a loss of $0.12, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Arbutus, which belongs to the Z ...